Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip24/7 Wall Street • 10/23/26
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential SymposiumBusiness Wire • 10/22/26
Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare TumorsBusiness Wire • 10/21/26
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)Business Wire • 10/21/26
Arcus Dips, But Recovers From Steep Losses, On Merck-Rivaling Cancer DataInvestors Business Daily • 10/20/26
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are WinningMarketBeat • 10/19/26
Big tech is wobbling. Goldman Sachs says it's time to buy these 23 unloved stocks instead.Market Watch • 10/19/26
Big pharma stocks near all-time highs as tech selloff pushes investors toward safer betsMarket Watch • 10/15/26
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending StockZacks Investment Research • 10/15/26
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to makeCNBC • 10/14/26
Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industryWSJ • 10/13/26
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma banBusiness Insider • 10/13/26
‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocksMarket Watch • 10/13/26